Response to the Letter to the Editor Entitled “Diagnostic Latency and Unmeasured Disease Severity In Male Lupus Nephritis” Authors: Kristina K Nasr, Ryan B Coopergard, Sisi Ma, Tak Mao Chan, Manish Rathi, Frederic A Houssiau, Zdenka Hruskova, Vivekanand Jha, Neil Solomons, Stephen M Korbet, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Vladimir Tesar, Matt Truman, Juan Mejia-Vilet, Melissa R West, Brad H Rovin, Patrick H Nachman Published: 2026 The Author Replies: We wish to thank Dr. Upadhyay1 for his interest in our study on sex differences in lupus nephritis and for the opportunity to respond to his comments regarding the potential role of diagnostic latency as a cause for lower estimated glomerular filtration rate in males with lupus nephritis.2 These comments reflect considerations central to our analysis of a large, international, and ethnically diverse lupus nephritis patient population. We addressed these questions within the limits of available data, as is inherent in retrospective and prospective cohort studies. As Dr. Upadhyay1 noted, our study acknowledges that the lower baseline estimated glomerular filtration rate in men may indicate more advanced renal scarring not captured by the ISN/Renal Pathology Society classification or available data. Diagnostic latency in systemic lupus erythematosus and lupus nephritis because of lower clinical suspicion in men is plausible, but the timing of onset for autoimmune diseases like systemic lupus erythematosus —with often nonspecific early symptoms—is difficult to ascertain. A prospective cohort study with systematic testing could provide clearer answers, but such studies are rarely feasible without substantial funding. We compared Systemic Lupus Erythematosus Disease Activity Index 2K scores at enrollment between sexes on the premise that more severe disease activity could indirectly reflect a delay in diagnosis in men compared with women. We found no significant sex differences in overall disease activity, even in data from robust randomized controlled trials with prospectively captured systemic Lupus Erythematosus Disease Activity Index data. Our study also details the challenges in interpreting relapse-free survival beyond the initial years of treatment. Beyond incomplete data, many confounders—such as access to healthcare, choice of maintenance or repeat courses of treatment and adherence to them, and sex differences in health-seeking behavior—complicate long-term outcome analysis. Although differences between sexes may indeed exist, identifying their causes beyond the first year of treatment remains speculative without more comprehensive data. Disclosure MT received consulting fees paid to his company from Aurinia Pharmaceuticals. NS was a former employee and shareholder of Aurinia and received stock options and consulting fees. MW is staff at the American Society of Nephrology. JM-V gave academic talks for AstraZeneca, Boehringer Ingelheim, Glaxo Smith Kline, Hoffman La Roche, and Novartis. VJ received payment or honoraria paid to his institute for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from Bayer, Boehringer Ingelheim, Vantive, Vera, Otsuka, Novartis, Astra Zeneca, Timberlyne, Takeda, and Biogen. BHR received grants paid to his institution from NIH, Lupus Research Association, Biogen, and consulting fees from Aurinia, Alexion, Astra Zeneca, Biogen, GSK, BMS, Roche-Genentech, Travere, Vera, Otsuka, Vertex, Calliditas, Century, Palleon, and Processa. BHR also received support from Vera, Genetech, and Kidney Disease: Improving Global Outcomes. TMC received unrestricted research grant from Astellas Pharma, consulting fees from Novartis, and support from Kyowa Kirin; he is the President at the Hong Kong College of Physicians. All the other authors declared no competing interests. References